surpass 3 tirzepatide AMRA Used in Analyses Evaluating the Effect on Muscle Composition via MRI SURPASS-CVOT Published: Large Trial Confirms

The elimination half-life is approximately 5-6 days in patients with overweight or obesity, and in patients with OSA and obesity

And I'm sure you've seen this in your training

This rebound effect is one reason why weight loss medication is considered a long-term treatment rather than a temporary intervention

However, for those who can tolerate the initial side effects, the weight loss and health benefits can be substantial

Safety Comparison Table# Research Evidence Comparison# CT-388 Research# CT-388 has early but notable clinical data: Phase 1b: Multi-arm, multi-cohort trial in adults with overweight/obesity and adults with obesity and T2D